UK markets closed

Amryt Pharma plc (AMYT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.14-0.07 (-0.62%)
At close: 4:00PM EDT
11.14 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.21
Open11.04
Bid10.28 x 800
Ask11.97 x 800
Day's range10.78 - 11.49
52-week range9.55 - 15.44
Volume247,020
Avg. volume114,589
Market cap721.116M
Beta (5Y monthly)0.11
PE ratio (TTM)N/A
EPS (TTM)-2.38
Earnings date06 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.67
  • Globe Newswire

    Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3

    Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3 DUBLIN, Ireland, and Boston MA, October 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the third quarter 2021 will be released on Wednesday, November 3, 2021 at 0700 EDT/1100 GMT. Amryt will host a conference call and webc

  • Globe Newswire

    Amryt Announces New Patents for Oleogel-S10 and Mycapssa®

    Amryt Announces New Patents for Oleogel-S10 and Mycapssa® DUBLIN, Ireland, and Boston MA, October 19, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its lead development candidate, Oleogel-S10, and its recently acquired and third commercial product, Mycapssa®. Oleogel-S10 The United States Patent and Trademark Office

  • Globe Newswire

    Total Voting Rights

    Total Voting Rights DUBLIN, Ireland, and Boston MA, October 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces that on September 30, 2021 the issued share capital of the Company comprised 316,904,642 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting right